The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Arsenal IO; Beigene; Elucida Oncology; Imvaq Therapeutics; Kleo Pharmaceuticals; Linnaeus Therapeutics; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.
Honoraria - American Association for Cancer Research; Esanex; Institut Jules Bordet
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Apricity Therapeutics; Array BioPharma; Ascentage Pharma; Astellas Pharma; Bayer; Beigene; Bristol-Myers Squibb; Chugai Pharma; F-Star Biotechnology; Genentech; Lilly; MedImmune; Merck; Neon Therapeutics; PsiOxus Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax; Tizona Therapeutics, Inc.; Trieza Therapeutics; Truvax
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2; Engineered Vaccinia Viruses for Cancer Immunotherapy; I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells.; I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer; I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.; I am co-inventor and receive royalties for a patent for immune modulating antibodies.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; MedImmune; Novartis; Ono Pharmaceutical; Potenza Therapeutics; Roche; Tizona Therapeutics, Inc.
 
Vanna Chiarion-Sileni
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Rene Gonzalez
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Johnson & Johnson; Lilly; Merck; Novartis; Pfizer; Procter & Gamble; Sanofi
Consulting or Advisory Role - Amgen
Research Funding - Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exicure (Inst); Immunocore (Inst); Incyte (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); Moderna Therapeutics (Inst); Morphotek (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech; Senhwa Biosciences (Inst); Syndax (Inst); Synlogic (Inst); Taiga (Inst); Takeda (Inst); Tesaro (Inst); Ultimovacs (Inst)
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Lilly; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sanofi
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Lilly; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Christopher D. Lao
Consulting or Advisory Role - BMS; Immunocore
Research Funding - Bristol-Myers Squibb; Dynavax Technologies; Genentech
Travel, Accommodations, Expenses - BMS; Immunocore
 
Charles Lance Cowey
Employment - Texas Oncology; US Oncology
Leadership - US Oncology
Honoraria - Merck
Consulting or Advisory Role - Iovance Biotherapeutics; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Seagen (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
John Wagstaff
Honoraria - AVEO; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Novartis; Pierre Fabre
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Novartis; Pierre Fabre
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Pierre Fabre
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Pier Francesco Ferrucci
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Research Funding - BMS (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Michael Smylie
Honoraria - Bristol-Myers Squibb; EMD Serono; Merck; Novartis; Pfizer
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; Iovance Biotherapeutics; LaRoche Posay; Merck; Novartis; Sanofi; Sun Pharma
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Andrew Graham Hill
Employment - Tasman Oncology
Stock and Other Ownership Interests - Tasman Oncology
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Ivan Marquez-Rodas
Consulting or Advisory Role - Amgen; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Incyte; Merck Serono; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi
Travel, Accommodations, Expenses - Bioncotech; Bristol-Myers Squibb; MSD; Roche
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AIMM Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Tuba Bas
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Consulting or Advisory Role - Fiore Healthcare Advisors (I)
 
Wim van Dijck
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
James Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Checkpoint THerapeutics; Compass Therapeutics; Eisai; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche